MedPath

The pilot study of SGLT2 selective inhibitor therapy for NAFLD patients who were complicated with T2DM

Not Applicable
Conditions
AFLD patients who were complicated with T2DM
Registration Number
JPRN-UMIN000023574
Lead Sponsor
Department of Hepatology, Shimane University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Chronic liver disease cases other than the non-alcoholic fatty liver disease.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
HbA1c after 6 months from the start of the administration.
Secondary Outcome Measures
NameTimeMethod
Body weight, body composition, ASTand ALT after 6 months from the start of the administration.
© Copyright 2025. All Rights Reserved by MedPath